glp 1 kidney disease GLP-1 Receptor Agonists and Diabetic Disease: A Call of Attention to Nephrologists Mechanisms of GLP-1 receptor–independent renoprotective
Description
doi: 10.1186/s12933-021-01386-4
Over 60% of sales in 2025 were via prescription-linked nutrition therapy
Key findings, including the potential protective effects of GLP-1RAs on schizophrenia, anxiety disorders, and autism, were consistently observed across multiple independent datasets, reinforcing the robustness and reproducibility of the results
The current available information on Lixisenatide is that it was tested and it is safe for diabetes, however it was removed from the market as a result of a business decision. Why are we interested in GLP-1 diabetes drugs for Parkinsons disease
